PMID: 41575937 bioRxiv2024 June 12
Both sound beneficial until you consider they operate in every tissue
The therapeutic potential of PRP is primarily mediated by its high concentration of growth factors, such as TGF-1, IGF, and VEGF, which regulate angiogenesis, cellular proliferation, anti-apoptotic signaling, and tissue remodeling
Compounds such as GHK-Cu have been developed to explore signalling pathways and peptide interactions in controlled laboratory environments
[16] DPP-4 inhibitors (such as sitagliptin), which enhance incretin activity through a different mechanism Insulin therapy, particularly if oral agents and other injectables are unsuitable Traditional agents like metformin, sulphonylureas, or pioglitazone, depending on individual circumstances NICE guideline NG28 recommends individualised treatment approaches based on HbA1c targets, cardiovascular risk, renal function, and patient preferences